Amylyx Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Amylyx Pharmaceuticals, Inc. (AMLX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 125.49 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 51.15K shares, a 11.95% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 74.34K shares, a 45.08% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 160.08K shares, a 71.77% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 228.79K shares, a 90.32% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 582.32K shares, a 88.25% decline from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 4.96M shares, a 868.14% increase from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 512.02K shares, a 251.26% increase from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 145.77K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 51.15K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 125.49K shares 10-Q · filed 2026-08-06 | 285.57K shares derived: sum of 3 quarters · filed 2026-08-06 | 514.36K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 74.34K shares 10-Q · filed 2026-05-07 | 234.42K shares derived: sum of 2 quarters · filed 2026-05-07 | 463.21K shares derived: sum of 3 quarters · filed 2026-05-07 | 521.30K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 160.08K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 388.87K shares derived: sum of 2 quarters · filed 2026-03-03 | 446.96K shares derived: sum of 3 quarters · filed 2026-03-03 | 582.32K shares 10-K · filed 2026-03-03 |
| 2025-09-30 | 228.79K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 286.88K shares derived: sum of 2 quarters · filed 2025-11-06 | 422.24K shares 10-Q · filed 2025-11-06 | 989.34K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 58.09K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 193.45K shares 10-Q · filed 2025-08-07 | 760.55K shares derived: sum of 3 quarters · filed 2025-08-07 | 3.13M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 135.36K shares 10-Q · filed 2025-05-08 | 702.46K shares derived: sum of 2 quarters · filed 2025-05-08 | 3.07M shares derived: sum of 3 quarters · filed 2025-05-08 | 4.74M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 567.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | 2.93M shares derived: sum of 2 quarters · filed 2025-03-04 | 4.60M shares derived: sum of 3 quarters · filed 2025-03-04 | 4.96M shares 10-K · filed 2025-03-04 |
| 2024-09-30 | 2.36M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 4.03M shares derived: sum of 2 quarters · filed 2024-11-07 | 4.39M shares 10-Q · filed 2024-11-07 | 4.64M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 1.67M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 2.03M shares 10-Q · filed 2024-08-08 | 2.27M shares derived: sum of 3 quarters · filed 2024-08-08 | 2.33M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 356.11K shares 10-Q · filed 2024-05-09 | 601.25K shares derived: sum of 2 quarters · filed 2024-05-09 | 657.41K shares derived: sum of 3 quarters · filed 2024-05-09 | 794.48K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 245.14K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | 301.30K shares derived: sum of 2 quarters · filed 2024-02-22 | 438.37K shares derived: sum of 3 quarters · filed 2024-02-22 | 512.02K shares 10-K · filed 2024-02-22 |
| 2023-09-30 | 56.16K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 193.23K shares derived: sum of 2 quarters · filed 2023-11-09 | 266.88K shares 10-Q · filed 2023-11-09 | 349.41K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 137.07K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 210.72K shares 10-Q · filed 2023-08-10 | 293.25K shares derived: sum of 3 quarters · filed 2023-08-10 | 342.04K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 73.66K shares 10-Q · filed 2023-05-11 | 156.18K shares derived: sum of 2 quarters · filed 2023-05-11 | 204.97K shares derived: sum of 3 quarters · filed 2023-05-11 | 215.37K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 82.53K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | 131.32K shares derived: sum of 2 quarters · filed 2023-03-13 | 141.72K shares derived: sum of 3 quarters · filed 2023-03-13 | 145.77K shares 10-K · filed 2023-03-13 |
| 2022-09-30 | 48.79K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 59.19K shares derived: sum of 2 quarters · filed 2022-11-10 | 63.24K shares 10-Q · filed 2022-11-10 | |
| 2022-06-30 | 10.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 14.45K shares 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | 4.05K shares 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |